Medical-device company ZimVie lowers sales guidance as losses grow

WESTMINSTER — ZimVie Inc. (Nasdaq: ZIMV), a Westminster-based dental and spine-centric medical-device company spun off this year from Zimmer Biomet Holdings Inc. (NYSE and SIX: ZBH), is projecting a lower sales total for 2022 as it posted a growing net loss in the second quarter. 

The company posted $233.4 million in revenue for the period, a decrease of 11.5% from the $263.6 million sales total in the second quarter of 2021.

ZimVie’s net loss for the quarter was $8.7 million, compared with a loss of $4.7 million in the same period last year. 

SPONSORED CONTENT

Empowering communities

Rocky Mountain Health Plans (RMHP), part of the UnitedHealthcare family, has pledged its commitment to uplift these communities through substantial investments in organizations addressing the distinct needs of our communities.

Sales guidance for full-year 2022 has been revised down from $1 billion to $915 million to $930 million.

“We continue to make progress towards our most vital commercial initiatives in both our dental and spine segments. Within dental, we recently launched two highly innovative products: the T3 PRO Tapered Implant and the Encode Emergence Healing Abutment. Within spine, we received a major positive insurance policy decision from Anthem Blue Cross Blue Shield for The Tether, a device for treatment of pediatric scoliosis, expanding insurance coverage for up to 30 million lives,” ZimVie CEO Vafa Jamali said in a prepared statement. “We are also tracking to our plan to improve the short- and long-term operational efficiency of our newly independent company.”

ZimVie’s stock has plummeted in the months since it spun off from Indiana-based Zimmer Biomet, dropping from a high of more than $45 per share in mid-February to less than $20 in mid-August.